He is the director of Gynecologic Cancer Research and of the Gynecologic Oncology Fellowship Program at Ohio State. After graduating from the University of Michigan, he attended Georgetown University School of Medicine in Washington, D.C., and completed his residency in obstetrics and gynecology at the University of Washington Medical Center in Seattle. He completed his fellowship in gynecologic oncology at Washington University in St. Louis.
Dr. Cohn’s interests include investigation of comparative effectiveness and cost-effective treatments for gynecologic cancers. He is the co-chair of the Gynecologic Oncology Group’s Health Outcomes Research Committee and chair of the Society of Gynecologic Oncology’s Education Committee.
- Named to the Castle Connolly list of America’s “Top Doctors” for 2015
- Rated in the top 10 percent of physicians in the nation for patient satisfaction, 2016
Georgetown University School of Medicine
Obstetrics / Gynecology
University of Washington Medical Ctr
7/1/1995 - 6/30/1998
Specialties and conditions I treat
- Gynecologic Oncology
- Gynecologic Cancers
- Ovarian Cancers
- Uterine Cancers
- Minimally Invasive Surgical Procedures
- Endometrial Cancers
- Cervical Cancer
- Vaginal Cancers
- Vulvar Cancers
Locations where I practice
JamesCare Gynecologic Oncology at Mill Run
More about my work
OB/GYN / Gynecological Oncology
Washington University Hospital
7/1/1998 - 6/30/2001
American Board of OB/GYN
American Board of OB/GYN (Subspecialty: Gynecologic Oncology)
News about me
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.
As of 03/25/2016, Dr. Cohn has reported no financial relationships with medical device, research and/or drug companies.